Cantor Fitzgerald analyst Joshua Schimmer reiterated a Buy rating on Trevi Therapeutics today and set a price target of $25.00. Meet Your ETF AI Analyst. Discover how TipRanks' ET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback